tiopronin
Trade name: thiola
Approved
Aug 11, 1988
Tiopronin is a prescription thiol drug used primarily in the treatment of severe homozygous cystinuria. Patients with cystinuria excrete high levels of cystine in their urine and are at risk for kidney stone formation. Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation. It is used after a failure of the non-pharmacological first line treatment consisting of increased fluid intake, restriction of sodium and protein, and urinary alkalinization. As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. It is similar to d-penicillamine in use and efficacy, but offers the advantage of far less adverse effects. Tiopronin is dosed on an individual basis using close monitoring of urinary cystine concentrations and urinary output. Tiopronin is a chelating agent. It works by removing extra cystine (the cause of kidney stones) from the urine, which keeps the kidney stones from forming. It works by reacting with urinary cysteine to form a more soluble, disulfide linked, tiopronin-cysteine complex. — NCATS
Clinical trial activity
5 trials · 12 clinical orgs · 9 marketing orgs
Earliest trial started Dec 1, 2007 (NCT02734966)
Timeline
1980s
- Jan 17, 1986
Orphan Drug Designation
- Aug 11, 1988
Mission Pharmacal — Earliest FDA Approval
- Aug 11, 1988
Mission Pharmacal — NDA Organization
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
2010s
- Jun 28, 2019
Mission Pharmacal — NDA Secondary Org
- Jun 28, 2019
Mission Pharmacal — Marketing Organization
2020s
- Apr 26, 2021
Teva — Marketing Organization
- Jun 2, 2022
Par Pharmaceuticals — Marketing Organization
- Jun 2, 2022
Endo Pharmaceuticals — Marketing Organization
- Jun 2, 2022
Bristol-Myers Squibb — Marketing Organization
- Jun 2, 2022
PH HEALTH — Marketing Organization
- Aug 15, 2023
Amneal Pharmaceuticals — Marketing Organization
- Jan 30, 2024
Torrent Pharmaceuticals Limited — Marketing Organization
- Jun 2, 2026
Casper Pharma LLC — Marketing Organization
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Reducing agent
Prevents cysteine excretion
Approval history
- approvedPriority reviewAug 11, 1988
Chemistry & pharmacology
SMILES
CC(S)C(=O)NCC(O)=O- Mol. weight
- 163.195 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaTiopronin ↗
- NCATSC5W04GO61S ↗
- ChEMBLCHEMBL1314 ↗
Also known as
- acadione
- acadione
- acadione
- alpha-mercaptopropionylglycine
- alpha-mercaptopropionylglycine
- alpha-mercaptopropionylglycine
- alpha-mpg
- capen
- captimer
- captimer
- captimer
- hepadigest
- mercaptopropionylglycine
- thiola
- thiola
- thiola
- thiolpropionamidoacetic acid
- thiopronin
- thiopronine
- tiopronin
- tiopronin
- tiopronin
- tiopronin
- tiopronin
- tiopronin
- tiopronin
- tiopronin
- tiopronin
- tiopronin
- tiopronin
- (+/-)-tiopronin
- tiopronine
- tiopronine
- tiopronine
- α-mpg
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03663855 | Phase 2 | Dec 31, 2018 | New York University |
| NCT03879759 | Phase 2 | Aug 22, 2018 | Macquarie University, National Health and Medical Research Council, Australia, South West Sydney Local Health District, Sydney Local Health District, University of Sydney |
| NCT02125721 | N/A | Jun 1, 2012 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), New York University |
| NCT01095731 | Phase 2 | Apr 1, 2010 | Columbia University, University of Florida, University of Washington |
| NCT02734966 | Phase 2 | Dec 1, 2007 | Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Jiao Tong University |
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| New York University | Academic/Hospital | 2 | 2 | 2 | 2012 |
| Columbia University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd | For profit | 1 | 1 | 1 | 2007 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2007 |
| Macquarie University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| National Health and Medical Research Council, Australia | Government | 1 | 0 | 1 | 2018 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2012 |
| South West Sydney Local Health District | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Sydney Local Health District | Government | 1 | 0 | 1 | 2018 |
| University of Florida | Academic/Hospital | 1 | 0 | 1 | 2010 |
| University of Sydney | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Washington | Academic/Hospital | 1 | 0 | 1 | 2010 |
Marketing (13)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Amneal Pharmaceuticals | For profit | MKTG | Aug 15, 2023 |
| Bristol-Myers Squibb | For profit | MKTG | Jun 2, 2022 |
| Casper Pharma LLC | For profit | MKTG | Jun 2, 2026 |
| Endo Pharmaceuticals | For profit | MKTG | Jun 2, 2022 |
| Mission Pharmacal | For profit | NDA | Aug 11, 1988 |
| Mission Pharmacal | For profit | NDA2 | Jun 28, 2019 |
| Mission Pharmacal | For profit | MKTG | Jun 28, 2019 |
| PH HEALTH | For profit | MKTG | Jun 2, 2022 |
| Par Pharmaceuticals | For profit | MKTG | Jun 2, 2022 |
| Par Pharmaceuticals | For profit | SYN | Feb 24, 2023 |
| Teva | For profit | MKTG | Apr 26, 2021 |
| Teva | For profit | SYN | Jul 22, 2024 |
| Torrent Pharmaceuticals Limited | For profit | MKTG | Jan 30, 2024 |